Soo Hee Jeong

Dr. Soo Hee Jeong


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2014 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
SJSoo Hee Jeong
Soo Hee Jeong
DNDavid Newcombe
David Newcombe
JSJanie Sheridan
Janie Sheridan
MTMalcolm Tingle
Malcolm Tingle

19 June 2019 in Xenobiotica
Verified
Journal Article
Closed access
SJSoo Hee Jeong
Soo Hee Jeong
JSJanie Sheridan
Janie Sheridan
CBChristopher Bullen
Christopher Bullen
DNDavid Alexander Leonard Newcombe
David Alexander Leonard Newcombe
NWNatalie Walker
Natalie Walker
MTMalcolm Tingle
Malcolm Tingle
1. Cytisine, a partial agonist for the α4β2-nAChR, is used as a smoking cessation medication. Cytisine’s current dosing is complex and involves taking 1.5 mg several times a day. The aim of this study was to explore the effect of dose on the pharmacokinetics and safety of cytisine after a single dose in healthy adult smokers. 2. Participants were assigned to one of three groups (n = 6 in each group) to receive a single oral dose of 1.5, 3 or 4.5 mg of cytisine. Blood samples were collected up to 24 h post dose. Pulse, blood pressure and respiratory rate were measured. Adverse effects were recorded. 3. Cytisine reached peak plasma concentration 1–2 h post dose in all participants irrespective of dose, with no dose-dependent changes in the elimination phase. Mean (SD) cytisine exposure (AUC0–24h) were 81.9 (15.8), 181.9 (40.8) and 254.5 (48.1) ng.h/mL following 1.5, 3 and 4.5 mg, respectively. 4. Cytisine appears to have predictable pharmacokinetics following a single dose of up to 4.5 mg and may be safe given as a single 4.5 mg dose, which is threefold greater than the recommended dose taken at one time. This study is registered in ClinicalTrials.gov (ID:NCT02585024).

2 December 2017 in Xenobiotica
Verified
Journal Article
Closed access
SJSoo Hee Jeong
Soo Hee Jeong
JSJanie Sheridan
Janie Sheridan
DNDavid Newcombe
David Newcombe
MTMalcolm Tingle
Malcolm Tingle
1. Cytisine is a plant alkaloid that is a partial agonist for the α4β2 -nAChRs and is used as an aid to smoking cessation. To date, there are no published data on cytisine concentrations in humans following multiple dosing. The aim of this study was to determine cytisine plasma concentrations after taking recommended doses for smoking cessation and to report on adverse effects. 2. Subjects (n=10) were instructed to follow the 25-day standard dosing regimen of cytisine. Blood was collected at 0, 2, 4, 8 and 10 hours on day 1 then on subsequent visits (days 2, 3, 4, 6, 13, 14, 17, 18, 21, 22, 25 and 26) to measure plasma cytisine concentrations. Plasma concentrations were determined using a validated LC-MS method. 3. Accumulation of cytisine was observed with repeated dosing of cytisine on day 1. Mean ± SEM plasma cytisine concentration measured at 10 hours was 50.8 ± 4.7 ng/mL. Due to dose tapering, there was an overall decrease in plasma cytisine concentration over the whole treatment period. 4. Overall, cytisine was well-tolerated and adverse effects reported were minor, indicating that cytisine is safe at concentrations measured in this study. This study is registered in the Australia and New Zealand Clinical Trials Registry (ACTRN12613000002785).

9 March 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KBKatie Burns
Katie Burns
OCOttiniel Chavani
Ottiniel Chavani
SJSoo Hee Jeong
Soo Hee Jeong
JDJohn A. Duley
John A. Duley
DPDavid Porter
David Porter
NHNuala A. Helsby
Nuala A. Helsby


18 February 2026 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
DDDimitri Daldegan-Bueno
Dimitri Daldegan-Bueno
CDCarina Joy Donegan
Carina Joy Donegan
RSRachael Sumner
Rachael Sumner
AFAnna Forsyth
Anna Forsyth
SJSoo Hee Jeong
Soo Hee Jeong
SMSuresh Muthukumaraswamy
Suresh Muthukumaraswamy
Despite growing interest in microdosed psychedelics, clinical trial evidence remains limited. We present daily mood, subjective perception of effects, and pharmacokinetics from an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label trial in which participants reported a mean symptom reduction of 60%. Participants took 16 sublingual LSD doses: 8 μg onsite, with bloods collected at eight time-points, then twice weekly at home with titration (6-20 μg). Pharmacokinetic parameters were estimated using non-compartmental and compartmental modelling. Daily questionnaires were used to assess depression severity with the self-reported Hamilton Depression Rating Scale (HAMD6), and mood with visual analogue scales (VAS). Drug effects were recorded with VAS scales on each dosing day. Linear mixed models were used to compare dosing days to one- and two-day post-dosing, and to identify linear trends (tolerance/sensitisation) of drug effects. Nineteen participants (males n = 15, 79%) received the intervention. Daily VAS indicated increased scores of mood-related states (e.g., more creative, happier) on dosing days (p = 0.009 to 0.039), but not in depression (p = 0.291). There was no indication of tolerance or sensitisation (p > 0.081). Non-compartmental AUC0-tlast was 836 ± 319 pg.h/mL, Cmax 212 ± 77.7 pg/mL and Tmax 1.17 ± 0.56 h. Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.